You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Request a contact

Login-link

Live Chat

For your patients with COPD who have experienced at least one exacerbation in the last 12 months despite ICS/LABA or LAMA/LABA maintenance therapy, TRELEGY Ellipta could make a difference. 1 2

Explore the evidence to see why.

  • TRELEGY Ellipta offers statistically superior exacerbation reduction vs. an ICS/LABA (BUD/FOR 320/9 mcg) BD [2]

    In the FULFIL study, TRELEGY Ellipta reduced the annual rate of moderate/severe exacerbations vs. BUD/FOR BD at 24 weeks 2

    Adapted from Lipson et al. 2017. 2

    The co-primary endpoints of change from baseline in trough FEV1 and SGRQ score at Week 24 were both met in this study. 2

  • TRELEGY Ellipta provides statistically superior exacerbation rate reduction vs. an ICS/LABA (FF/VI 92/22 mcg) OD [1]

    In the landmark IMPACT trial, TRELEGY Ellipta reduced the annual rate of moderate/severe exacerbations vs. FF/VI at 52 weeks 1

    Adapted from Lipson et al. 2018 1

    What could this mean for your patients?

    With TRELEGY Ellipta you could help prevent 1

    *Event-based NNT calculation. NNT is calculated from the reciprocal of the absolute rate reduction (TRELEGY Ellipta versus FF/VI 0.16), as calculated from data presented by Lipson et al 2018. 1

  • TRELEGY Ellipta provides statistically superior exacerbation rate reduction vs. a LAMA/LABA (UMEC/VI 55/22 mcg) OD [1]

    In the landmark IMPACT trial, TRELEGY Ellipta reduced the annual rate of moderate/severe exacerbations vs. UMEC/VI 1

    Adapted from Lipson et al. 2018. 1

    What could this mean for your patients?

    With TRELEGY Ellipta you can help prevent 1

    *Event-based NNT calculation. NNT is calculated from the reciprocal of the absolute rate reduction (TRELEGY Ellipta versus UMEC/VI 1/0.30), as calculated from data presented by Lipson et al 2018. 1

  • Watch Professor Paul Jones give an overview of the IMPACT trial (3 min video)

    Watch Professor Paul Jones give an overview of the IMPACT trial (3 min video)

    Video player requires JavaScript enabled. You can download this video here: https://videos.gskstatic.com/pharma/GSKpro/Ireland/MP4/IE-9446000_Video_D4.mp4 https://videos.gskstatic.com/pharma/GSKpro/Ireland/WEBM/IE-9446000_Video_D4.webm https://videos.gskstatic.com/pharma/GSKpro/Ireland/OGV/IE-9446000_Video_D4.ogv

  • Overview of the IMPACT trial [1] [3]

    IMPACT was the first Phase III, randomised, double-blind, parallel-group, multicentre, 52-week trial to assess the efficacy and safety of the single-inhaler Triple Therapy TRELEGY Ellipta vs. an ICS/LABA (FF/VI 92/22 mcg) and vs. a LAMA/LABA (UMEC/VI 55/22 mcg) in symptomatic patients on COPD maintenance treatments who had experienced at least one exacerbation in the last 12 months. 1 4

    Primary endpoint 1

    Annual rate of on-treatment moderate/severe COPD exacerbations for TRELEGY Ellipta vs. both comparators.

    Other key endpoints 1

    • Lung function: change from baseline in trough FEV1 at Week 52 1, 3
    • Health-related quality of life: change from baseline in SGRQ score at Week 52 1, 3

    Key inclusion criteriqa 1 3

    Patients aged 40 years or older with COPD and a CAT score ≥10 with:

    • FEV1 <50% predicted and >1 moderate/severe exacerbations in the previous year, or
    • FEV1 ≥50% to <80% predicted and ≥2 moderate exacerbation or ≥1 severe exacerbation in the previous year
    • Patients were required to be receiving daily maintenance therapy for COPD for at least 3 months prior to screening

    Key exclusion criteria 1 3

    Patients were excluded if they had any of the following:

    • a current diagnosis of asthma or other respiratory disorders
    • pneumonia or other respiratory tract infection unresolved ≤14 days or ≤7 days, respectively, prior to screening
    • unresolved exacerbation ≤14 days prior to screening
    • oral/systemic corticosteroid use ≤30 days prior to screening

  • Overview of the FULFIL study [2]

    The efficacy and safety of TRELEGY Ellipta OD was compared in the FULFIL study with budesonide/formoterol (BUD/FOR, 320/9 mcg BD).2

    The FULFIL study was a Phase III, randomised, double-blind, double-dummy, parallel-group, multicentre, 24-week study. Patients underwent a 2-week run-in period, during which medications at screening were unchanged from their pre-study COPD maintenance therapy, followed by a 24-week treatment period.2

    A subset of 430 patients (TRELEGY Ellipta OD n=210, BUD/FOR 320/9 mcg) BD n=220 remained on blinded study treatment for up to 52 weeks (the EXT population). Efficacy endpoints and safety were assessed up to Week 52 in the EXT population.2

    Co-primary endpoints2

    • Change from baseline in trough FEV1 and SGRQ score at Week 24

    Some secondary/other endpoints2

    • Annual rate of moderate/severe COPD exacerbations
    • Change from baseline CAT score

    Key inclusion criteria2

    • Patients with COPD with FEV1 <50% and CAT score ≥10, or
    • Patients with FEV1 ≥50% to <80% and CAT score ≥10, and either ≥2 moderate exacerbations in the past year or ≥1 severe exacerbation in the past year
    • Aged ≥40 years old

    Key exclusion criteria2

    • Current diagnosis of asthma causing patient symptoms
    • Unresolved pneumonia or severe COPD exacerbation

Moderate exacerbation was an exacerbation that required antibiotics or systemic gluticoricoids. Severe exacerbation was an exacerbation that led to hospitalisation or death

More efficacy data:

Discover lung function results >

See the health-related quality of life results >


Abbreviations:

BD, twice-daily; BUD, budesonide; CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; EXT, extension; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; NNT, number needed to treat; OD, once-daily; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol.

References:

  1. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
  2. Lipson DA et al. Am J Respir Crit Care Med 2017; 196(4):438–446.
  3. Lipson DA et al. N Engl J Med 2018; 378:1671–1680 (supplementary material).
  4. Lipson DA et al. N Engl J Med 2018; 378:1671–1680 (supplementary material protocol).
  5. TRELEGY Ellipta SmPC 2018, Available at www.medicines.ie [Accessed January 2020]
  6. Relvar Ellipta (fluticasone furoate/vilanterol 92/22 mcg) SmPC, 2018. Available at www.medicines.ie [Accessed January 2020]
  7. Anoro▼ Ellipta (umeclidinium/vilanterol 55/22 mcg) SmPC, 2018. Available at www.medicines.ie [Accessed January 2020]

Trelegy Ellipta Prescribing information 

Relvar Ellipta Prescribing information

Anoro Ellipta Prescribing information

TRELEGY Ellipta, Relvar Ellipta and Anoro Ellipta were developed in collaboration with INNOVIVA Inc.

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

© 2019 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners

TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe COPD who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA 5

Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy 6

Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD 7